Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 Inhibitor Portfolio News / By Karina Tin June 22, 2020
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials Portfolio News / By Karina Tin June 19, 2020
Rapt Therapeutics Appoints Peter Svennilson to Board of Directors Portfolio News / By Karina Tin June 18, 2020
Revolution Medicines Appoints Peter Svennilson to its Board of Directors Portfolio News / By Karina Tin June 18, 2020
Nurix Therapeutics Announces Addition of Immuno-Oncology Clinical Experts to its Management Team Portfolio News / By Karina Tin June 16, 2020
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock Portfolio News / By Karina Tin June 16, 2020
Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise Portfolio News / By Karina Tin June 12, 2020
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510 Portfolio News / By Karina Tin June 9, 2020
Accent Therapeutics and AstraZeneca to Discover and Develop Novel Cancer Therapeutics in New Collaboration Portfolio News / By Karina Tin June 4, 2020
